Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Selected Articles from This Issue

DOI:  Published January 2021
  • Article
  • Info & Metrics
  • PDF
Loading

Sertraline Targets Serine/Glycine Synthesis Enzyme SHMT

Geeraerts et al. Page 50

Healthy cells typically take up serine and glycine from their environment. By contrast, several cancers are metabolically addicted to endogenous serine/glycine synthesis to sustain their proliferation. This dependence on serine/glycine synthesis in cancer thus offers an attractive drug target. Previously developed serine/glycine synthesis inhibitors did not pass clinical trials due to unfavorable pharmacokinetic profiles. By utilizing a drug repurposing screen, Geeraerts and colleagues found that the clinically used antidepressant sertraline inhibits serine/glycine synthesis enzyme SHMT and selectively suppresses proliferation of serine/glycine synthesis addicted cancer cells. Furthermore, simultaneous inhibition of serine/glycine synthesis and mitochondrial metabolism offers a novel treatment strategy for these cancers.

PIM Kinases Promote Resistance to Therapy

Toth et al. Page 3

PIM kinases are oncogenic serine/threonine kinases that control cellular metabolism, proliferation, and survival. Due to their commonality in many cancer subtypes, efforts have focused at inhibiting PIM kinases. In this review article, Toth and Warfel outline the known signaling pathways through which PIM kinase operates as well as the current efforts to inhibit their function. They detail the role of PIM kinases in resistance to therapies such as PI3K/mTOR and angiogenesis inhibitors and the role of PIM inhibition in overcoming these resistances.

HLA Polymorphisms Predict TFR in CML

Ureshino et al. Page 142

The determinants of treatment-free remission (TFR) remain elusive in chronic phase chronic myeloid leukemia (CML-CP). In this study, Ureshino and colleagues assess polymorphisms in killer immunoglobulin-like receptors (KIRs) and human leukocyte antigens (HLAs) as well as NK cell activation status in seventy-six patients. Their analysis revealed three HLA polymorphisms associated with TFR and that NK cell activation status contributed to deep molecular response (DMR). Taken together, their results suggest DMR depends on NK cell activation status and T-cell–mediated immunity contributes to TFR in CML-CP patients.

Hsp90 Inhibition and PD-1 Blockade in PDAC

Zhang et al. Page 150

Fibrotic stroma limits the ability to treat pancreatic ductal adenocarcinoma (PDAC) and results from the interaction of tumor cells, immune cells, and pancreatic stellate cells (PSCs) or cancer associated fibroblasts (CAF). Zhang and colleagues sought to inhibit inflammatory signals through Hsp90 inhibition. The Hsp90 inhibitor XL888 decreased levels of IL6, limited PSC/CAF growth, and reduced alpha-SMA expression. XL888 synergized with anti-PD-1 therapy in subcutaneous Panc02 and orthotopic KPC Luc tumors. Therefore, Hsp90 can reduce PSC/CAF signaling and enhance anti-PD-1 blockade in PDAC.

  • ©2021 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 20 (1)
January 2021
Volume 20, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selected Articles from This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selected Articles from This Issue
Mol Cancer Ther January 1 2021 (20) (1) 1;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selected Articles from This Issue
Mol Cancer Ther January 1 2021 (20) (1) 1;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Sertraline Targets Serine/Glycine Synthesis Enzyme SHMT
    • PIM Kinases Promote Resistance to Therapy
    • HLA Polymorphisms Predict TFR in CML
    • Hsp90 Inhibition and PD-1 Blockade in PDAC
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement